Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment

  title={Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment},
  author={Victoria C. Yan and Florian L. Muller},
  journal={ACS Medicinal Chemistry Letters},
  pages={1361 - 1366}
While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment. 

Figures from this paper

Phosphoramidate Prodrugs Continue to Deliver: The Journey of Remdesivir (GS-5734) from the Liver to Peripheral Blood Mononuclear Cells.

This work highlights the pharmacodynamic discordance of remdesivir between humans and non-human primates, thereby demonstrating that non- human primate disease models overestimate the therapeutic efficacy of phosphoramidate prodrugs.

Pharmacokinetics of Orally Administered GS-441524 in Dogs

The oral bioavailability of GS-441524 in beagle dogs is assessed and it is shown that plasma concentrations ∼24-fold higher than the EC50 against SARS-CoV-2 are easily and safely sustained.

Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19

D doses of GS‐441524 lower than the 13 mg/kg dose used in the first‐in‐human trial may be effective against Covid‐19 and appears to be well‐tolerated, and GS‐ 441524 has potential for oral treatment of Covid-19.

Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside

Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mice Models

The parent nucleotide of remdesivir, GS-441524, potently inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero E6 and other cells and supported that GS- 441524 as a promising and inexpensive drug candidate in the treatment of COVID-19 and future emerging CoVs diseases.

Remdesivir: Quo vadis?

Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs

New oral lipid prodrugs of Remdesivir nucleoside had submicromolar anti-SARS-CoV-2 activity in a variety of cell types including Vero E6, Calu-3, Caco-2, human pluripotent stem cell (PSC)-derived lung cells and Huh7.5 cells.

Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity.

Two of the three new lipid prodrugs of RVn had anti-SARS-CoV-2 activity 9 to 24 times greater than that of RDV in Vero E6 cells and likely improved oral bioavailability and simpler metabolic activation.